The Transplant Infectious Diseases Consult Service is composed of experienced transplant infectious diseases physicians. In collaboration with the Blood and Immune Deficiency Cellular Therapy Program (BID-CTP), a clinical initiative that spans across four institutes within NIH, and with the Experimental Transplantation and Immunology Branch (ETIB), the consult service provides direct patient care, educational support and develops institutional guidelines for the prevention and management of infections for patients undergoing hematopoietic stem cell transplant, gene or cellular therapies at the NIH clinical center.

Dr. Cuellar Rodriguez received her medical degree from the Universidad Autónoma de Guadalajara (Guadalajara, Mexico) in 1999 and her Diploma in Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine (London, UK) in 2003. She completed an Internal Medicine residency and Infectious Diseases fellowship at the at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) in Mexico City, followed by a Clinical Fellowship in Transplant Infectious Diseases at the Cleveland Clinic in Cleveland, OH. In 2009, she joined NIAID as a clinical fellow (visiting program) where she completed an advanced infectious diseases fellowship (academic/research track) in infections in immunocompromised host. She was later promoted to staff clinician in 2011. In 2014, Dr. Cuellar Rodriguez returned to the INCMNSZ to serve as head of the Transplant Infectious Diseases Section, within the Department of Infectious Disease, where she remained until 2019. She then returned to NIAID in the Division of Intramural Research and is now the director of the Transplant Infectious Diseases Consult Service.

Juan Gea-Banacloche, M.D., Staff Clinician
Mark Parta, M.D., MPHTM, Physician III

Visit PubMed for a complete publication listing.

NIAID Infectious Diseases Fellowship Program

The Immunopathogenesis Section therapeutic and research programs take a fully integrated approach to infectious disease, incorporating the molecular genetics of the host and the pathogen as well as mechanisms of pathogenesis that allow the development and study of novel therapeutics. The integrated bench-to-bedside model is intrinsic to the Immunopathogenesis Section approach and is reflected in the close involvement of trainees (both M.D. and Ph.D.) in laboratory work and in the clinical appreciation of disease, which together add new insights into mechanisms of action and avenues of therapy. New protocols in Coccidioides infections and pathogenesis of mycobacterial infections are in progress.

Dr. Holland received his M.D. from the Johns Hopkins University School of Medicine in 1983, where he stayed as a resident in internal medicine, assistant chief of service in medicine, and fellow in infectious diseases. He came to the National Institutes of Health in 1989 as a National Research Council fellow in the Laboratory of Molecular Microbiology, working on transcriptional regulation of HIV. In 1991, Dr. Holland joined the Laboratory of Host Defenses, shifting his research to the host side, with a focus on phagocyte defects and their associated infections. His work centered on the pathogenesis and management of chronic granulomatous disease, as well as other congenital immune defects affecting phagocytes, including those predisposing to mycobacterial diseases. He was chief of LCID from 2004 to 2016 and was selected as DIR director in 2016.

Li Ding, M.D.
Emilia Falcone, M.D.
Yu Han, Ph.D.
Alexandra F. Freeman, M.D.
Amy P. Hsu, B.A.
Beatriz Marciano, M.D.
Masashi Matsuyama, M.D., Ph.D.
Katelyn McCann, B.S.
Lindsey Rosen, B.S.
Gulbu Uzel, M.D.
Elizabeth P. Sampiao, M.D., Ph.D.
Christa S. Zerbe, M.D.
Ofer Zimmerman, M.D.

Kuhns DB, Fink DL, Choi U, Sweeney C, Lau K, Long Priel D, Riva D, Mendez L, Uzel G, Freeman AF, Olivier KN, Anderson VL, Currens R, Mackley V, Kang A, Al-Adeli M, Mace E, Orange JS, Kang E, Lockett SJ, Chen, Steinbach PJ, Hsu AP, Zarember KA, Malech HL, Gallin JI, Holland SM. Cytoskeletal abnormalities and neutrophil dysfunction in WDR1 deficiency. Blood. 2016 Aug 24. Epub ahead of print.

Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, Su HC, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee  J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM, Lenardo MJ, Tangye SG, Uzel G. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014 Sept 10;345(6204):1623-7.

Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, Arthur DC, Gu W, Gould CM, Brewer CC, Cowen EW, Freeman AF, Olivier KN, Uzel G, Zelazny AM, Daub JR, Spalding CD, Claypool RJ, Giri NK, Alter BP, Mace EM, Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014 Feb 6;123(6):809-21.

Sampaio EP, Hsu AP, Pechacek J, Bax HI, Dias DL, Paulson ML, Chandrasekaran P, Rosen LB, Carvalho DS, Ding L, Vinh DC, Browne SK, Datta S, Milner JD, Kuhns DB, Long Priel DA, Sadat MA, Shiloh M, De Marco B, Alvares M, Gillman JW, Ramarathnam V, de la Morena M, Bezrodnik L, Moreira I, Uzel G, Johnson D, Spalding C, Zerbe CS, Wiley H, Greenberg DE, Hoover SE, Rosenzweig SD, Galgiani JN, Holland SM. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol. 2013 Jun;131(6):1624-34.

Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, Kirk JL, Jutivorakool K, Zaman R, Ding L, Hsu AP, Patel SY, Olivier KN, Lulitanond V, Mootsikapun P, Anunnatsiri S, Angkasekwinai N, Sathapatayavongs B, Hsueh PR, Shieh CC, Brown MR, Thongnoppakhun W, Claypool R, Sampaio EP, Thepthai C, Waywa D, Dacombe C, Reizes Y, Zelazny AM, Saleeb P, Rosen LB, Mo A, Iadarola M, Holland SM. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med.2012 Aug 23;367(8):725-34.

Visit PubMed for a complete publication listing.

• Detection and Characterization of Infections and Infection Susceptibility
• Study of Mycobacterial Infections
• Study of Clinical Features and Genetics of Hyperimmunoglobulin E Recurrent Infection
• Detection and Characterization of Host Defense Defects
• Collection of Lung Fluid and Tissue Samples for Research
• Antibody Production in Immune Disorders
• Natural History of GATA2 Deficiency
• Natural History of Coccidiodomycosis (Valley Fever)

The prevalence of severe allergic disease is on the rise globally; consequently, severe systemic allergic inflammation and reactions are also becoming far more frequent, representing a major public health burden causing morbidity for patients, distress for families, and substantial costs for the healthcare system. We seek to develop methods and strategies to identify individuals at with or at high risk of developing severe allergic inflammation and anaphylaxis in order to identify specific pathways leading to these phenotypes and enable the development of new therapies that can successfully limit and/or prevent these potentially devastating consequences.

Dr. O'Connell received his Ph.D. in development origins of health and disease (cell and molecular biology) from the University of Southampton School of Medicine in the United Kingdom, in collaboration with the University of Pennsylvania. He obtained postdoctoral training in the areas of Wnt5a-mediated progression of metastatic melanoma at the National Institute on Aging from 2006 to 2011. Prior to joining the Laboratory of Allergic Diseases in 2014, Dr. O'Connell was a staff scientist at the Wistar Institute, Philadelphia, from 2011 to 2014, where he investigated mechanisms of drug resistance in cancer. Dr. O’Connell joined the Laboratory of Allergic Diseases from the Wistar Institute in 2015. Working in the Genetics and Pathology of Allergy Section, he has endothelial cell-driven mechanisms promoting atopy. He joined the Translational Allergic Immunopathology Unit in 2019 bringing with him expertise in molecular biology and cancer and is leading efforts to understand how inherited and acquired genetic variation in endothelial and myeloid cells can promote severe allergic reactions and myeloproliferation.

Desai, A., Sowerwine, K., Liu, Y., Lawrence, M.G., O’Connell, M.P., Chovanec, J., Hsu, A.P., Boris, L., Jones, N., Zerbe, C., Wisch, L., Maric, I., Lee, R.C., Gilfillan, A., Stone, K.D., Milner, J.D., Holland, S.M., Metcalfe, D.D., Lyons, J.J. GATA2-deficient mast cells limit type I hypersensitivity reactions in humans. J Allergy Clin Immunol. 2019 May 15.

Lyons, J.J., Liu, Y., Ma, C., Yu, X., O'Connell, M.P., Lawrence, M., Zhang, Y., Karpe, K., Zhao, M., Siegel, A., Stone, K.D., Nelson, C., Jones, N., Dimaggio, T., Darnell, D., Mendoza-Caamal, E., Orozco, L., Hughes, J., McElwee, J., Hohman, R., Frischmeyer-Guerrerio, P., Rothenberg, M., Freeman, A., Holland, S., and Milner, J.D. ERBIN deficiency links STAT3 and TGF-β pathway defects with atopy in humans. J Exp Med. 2017 Mar 6.

Lyons, J.J., Yu, X., Hughes, J.D., Le, Q.T., Jamil, A., Bai, Y., Ho, N., Zhao, M., Liu, Y., O'Connell, M.P., Trivedi, N.N., Nelson, C., DiMaggio, T., Jones, N., Matthews, H., Lewis, K.L., Oler, A.J., Carlson, R.J., Arkwright, P.D., Hong, C., Agama, S., Wilson, T.M., Tucker, S., Zhang, Y., McElwee, J.J., Pao, M., Glover, S.C., Rothenberg, M.E., Hohman, R.J., Stone, K.D., Caughey, G.H., Heller, T., Metcalfe, D.D., Biesecker, L.G., Schwartz, L.B., Milner, J.D. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016 Dec.

Kaur, A., Webster, M.R., Marchbank, K., Behera, R., Ndoye, A., Kugell III, C.H., Dang, V.M., Appleton, J., O’Connell, M.P., Cheng, P., Valiga, A.A., Morissette, R., McDonnell, N.B., Ferrucci, L., Kossenkov, A.V., Meeth, K., Tang, H., Yin, X., Wood III, W.H., Lehrmann, E., Becker, K.G., Flaherty, K.T., Frederick, D.T., Wargo, J.A., Cooper, Z.A., Tetzlaff, M.T., Hudgens, C., Aird, K.M., Zhang, R., Xu, X., Liu, Q., Bartlett, E., Karakousis, G., Eroglu, Z., Lo, R.S., Chan, M., Menzies, A.M., Long, G.V., Johnson, D.B., Sosman, J., Schilling, B., Schadendorf, D., Speicher, D.W., Bosenberg, M., Ribas, A., and Weeraratna, A.T. sFRP2 in the aged microenvironment drives melanoma metastasis and resistance to targeted therapy. Nature. 2016 Apr 14.

O’Connell, M.P.*, Hox, V.*, Lyons, J.J., Sackstein, P., Dimaggio, T., Jones, N., Nelson, C., Boehm, M., Holland, S.M., Freeman, A.F., Tweardy, D.J., Olivera, A., Metcalfe, D.D., Milner, J.D. Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis. J Allergy Clin Immunol. 2016 Jul;138(1):187-99. doi: 10.1016/j.jaci.2015.11.024. * Co-first author

O’Connell M.P., Marchbank K., Webster M.R., Valiga A., Kaur A.A., Vultur A.M., Li L., Herlyn M., Villanueva J., Liu Q., Yin X., Widura S., Nelson J., Ruiz N., Camilli T.C., Indig F.E., Flaherty K.T, Wargo J.A., Frederick D.T.,. Cooper Z.A., Nair S., Amaravadi R.K., Schuchter L.M., Karakousis G., Xu W., Xu X., Weeraratna A.T. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013 Dec;3(12):1378-93.

Visit PubMed for a complete publication listing.